Clinical trial / 2017
Oral nicotinamide reduced actinic keratosis size and prevented new lesions in organ transplant recipients over six months.
Thirty-eight transplant recipients with actinic keratoses (AKs) were randomly assigned to receive 500 mg daily oral nicotinamide (n=19) or no nicotinamide (n=19) for six months. At baseline, AK size did not differ significantly between groups. After six months, AKs significantly decreased in size in 18 of 19 treated patients (88%), with complete clinical regression in seven patients (42%) and no new AKs. In contrast, 91% of controls showed increased AK size and/or developed new AKs, and seven pre-existing AKs progressed to squamous-cell carcinoma.
- Study type
- Randomized controlled trial
- Who was studied
- 38 organ transplant recipients (8 liver, 30 kidney) with single or multiple actinic keratoses
- What was measured
- Change in actinic keratosis size, complete regression, development of new actinic keratoses, and progression to squamous-cell carcinoma
THE PAPER
Prevention of non-melanoma skin cancers with nicotinamide in transplant recipients: a case-control study.
Drago F, Ciccarese G, Cogorno L, Calvi C, Marsano LA, Parodi A. Eur J Dermatol, 2017.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.